{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:10:45Z","timestamp":1789582245890,"version":"build-2803163510"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/M016579\/1"],"award-info":[{"award-number":["MR\/M016579\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/M016579\/1"],"award-info":[{"award-number":["MR\/M016579\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>The past 25 years have seen huge progress in understanding of the pathobiology of type-2 (T2) asthma, identification of measurable biomarkers, and the emergence of novel monoclonal antibody treatments. Although present in a minority of patients with severe asthma, very little is known about the mechanisms underlying T2-low asthma, making it a significant unmet need in asthma research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objective of this study was to explore the differences between study exacerbators and nonexacerbators, to describe physiological changes at exacerbation in those who are T2HIGH and T2LOW at the time of exacerbation, and to evaluate the stability of inflammatory phenotypes when stable and at exacerbation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Exacerbation assessment was a prespecified secondary analysis of data from a 48-week, multicenter, randomized controlled clinical study comparing the use of biomarkers and symptoms to adjust steroid treatment in a T2-low severe asthma\u2013enriched cohort. Participants were phenotyped as T2LOW (fractional exhaled nitric oxide\u2009\u2a7d\u200920 ppb and blood eosinophil count\u2009\u2a7d\u2009150 cells\/\u00b5l) or T2HIGH (fractional exhaled nitric oxide\u2009&amp;gt;\u200920 or blood eosinophil count\u2009&amp;gt;\u2009150) at study enrollment and at each exacerbation. Here, we report the findings of the exacerbation analyses, including comparison of exacerbators and nonexacerbators, the physiological changes at exacerbation in those who had evidence of T2 biology at exacerbation versus those that did not, and the stability of inflammatory phenotypes when stable and at exacerbation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Of the 301 participants, 60.8% (183) had one or more self-reported exacerbations (total of 390). Exacerbators were more likely to be female, have a higher body mass index, and have more exacerbations requiring oral corticosteroid and unscheduled primary care attendances for exacerbations. At enrollment, 23.6% (71) were T2LOW and 76.4% (230) T2HIGH. The T2LOW group had more asthma primary care attendances, were more likely to have a previous admission to HDU (high dependency unit)\/ICU and to be receiving maintenance oral corticosteroids. At exacerbation, the T2LOW events were indistinguishable from T2HIGH exacerbations in terms of lung function (mean fall in T2LOW FEV1, 200 [400] ml vs. T2HIGH 200 [300] ml; P\u2009=\u20090.93) and symptom increase (ACQ5: T2LOW, 1.4 [0.8] vs. T2HIGH, 1.3 [0.8]; P\u2009=\u20090.72), with no increase in T2 biomarkers from stable to exacerbation state in the T2LOW exacerbations. The inflammatory phenotype within individual patients was dynamic; inflammatory phenotype at study entry did not have a significant association with exacerbation phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Asthma exacerbations demonstrating a T2LOW phenotype were physiologically and symptomatically similar to T2HIGH exacerbations. T2LOW asthma was an unstable phenotype, suggesting that exacerbation phenotyping should occur at the time of exacerbation. The clinically significant exacerbations in participants without evidence of T2 biology at the time of exacerbation highlight the unmet and pressing need to further understand the mechanisms at play in non-T2 asthma.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT02717689).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202201-0129oc","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T13:19:23Z","timestamp":1652361563000},"page":"545-553","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":56,"title":["Exacerbation Profile and Risk Factors in a Type-2\u2013Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes"],"prefix":"10.1093","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2063-7992","authenticated-orcid":false,"given":"P. Jane","family":"McDowell","sequence":"first","affiliation":[{"name":"Center for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen\u2019s University, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Busby","sequence":"additional","affiliation":[{"name":"Center for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen\u2019s University, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2453-6021","authenticated-orcid":false,"given":"Catherine E.","family":"Hanratty","sequence":"additional","affiliation":[{"name":"Center for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen\u2019s University, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6039-5612","authenticated-orcid":false,"given":"Ratko","family":"Djukanovic","sequence":"additional","affiliation":[{"name":"School of Clinical and Experimental Sciences, University of Southampton, National Institute for Health and Care Research (NIHR) Southampton Biomedical Research Center, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5428-8578","authenticated-orcid":false,"given":"Ashley","family":"Woodcock","sequence":"additional","affiliation":[{"name":"Manchester Academic Health Science Center and NIHR Manchester Biomedical Research Center, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Walker","sequence":"additional","affiliation":[{"name":"Asthma UK and British Lung Foundation Partnership, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1417-9019","authenticated-orcid":false,"given":"Timothy Colin","family":"Hardman","sequence":"additional","affiliation":[{"name":"Niche Science and Technology Ltd., Richmond, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7677-9979","authenticated-orcid":false,"given":"Joseph R.","family":"Arron","sequence":"additional","affiliation":[{"name":"Genentech Inc., San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Choy","sequence":"additional","affiliation":[{"name":"Genentech Inc., San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8403-0319","authenticated-orcid":false,"given":"Peter","family":"Bradding","sequence":"additional","affiliation":[{"name":"Department of Respiratory Sciences, Institute for Lung Health and Leicester NIHR Biomedical Research Center, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9345-4903","authenticated-orcid":false,"given":"Chris E.","family":"Brightling","sequence":"additional","affiliation":[{"name":"Department of Respiratory Sciences, Institute for Lung Health and Leicester NIHR Biomedical Research Center, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-949X","authenticated-orcid":false,"given":"Rekha","family":"Chaudhuri","sequence":"additional","affiliation":[{"name":"Gartnavel General Hospital, Glasgow and University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Cowan","sequence":"additional","affiliation":[{"name":"NHS Greater Glasgow and Clyde, Stobhill Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-8778","authenticated-orcid":false,"given":"Adel H.","family":"Mansur","sequence":"additional","affiliation":[{"name":"University of Birmingham and Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Manchester Academic Health Science Center and NIHR Manchester Biomedical Research Center, Manchester University Hospitals National Health Service (NHS) Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-5121","authenticated-orcid":false,"given":"Sarah E.","family":"Diver","sequence":"additional","affiliation":[{"name":"Department of Respiratory Sciences, Institute for Lung Health and Leicester NIHR Biomedical Research Center, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[{"name":"School of Clinical and Experimental Sciences, University of Southampton, National Institute for Health and Care Research (NIHR) Southampton Biomedical Research Center, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lordan","sequence":"additional","affiliation":[{"name":"the Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9707-4986","authenticated-orcid":false,"given":"Andrew","family":"Menzies-Gow","sequence":"additional","affiliation":[{"name":"Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, the University of Manchester, Royal Brompton and Harefield Hospitals, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Harrison","sequence":"additional","affiliation":[{"name":"Nottingham Respiratory NIHR Biomedical Research Center, University of Nottingham, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Robinson","sequence":"additional","affiliation":[{"name":"University College Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile T. J.","family":"Holweg","sequence":"additional","affiliation":[{"name":"Genentech Inc., San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Matthews","sequence":"additional","affiliation":[{"name":"23andMe, Sunnyvale, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-5973","authenticated-orcid":false,"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[{"name":"Oxford Respiratory NIHR Biomedical Research Center, Nuffield Department of Medicine, the University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9176-5564","authenticated-orcid":false,"given":"Liam G.","family":"Heaney","sequence":"additional","affiliation":[{"name":"Center for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen\u2019s University, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"2026022021164841700_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"2026022021164841700_bib2","year":"2019"},{"key":"2026022021164841700_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thoraxjnl-2015-207630","article-title":"Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry","volume":"71","author":"Sweeney","year":"2016","journal-title":"Thorax"},{"key":"2026022021164841700_bib4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/thoraxjnl-2013-204114","article-title":"The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry","volume":"70","author":"O\u2019Neill","year":"2015","journal-title":"Thorax"},{"key":"2026022021164841700_bib5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"2026022021164841700_bib6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaci.2013.06.007","article-title":"Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects","volume":"132","author":"Malinovschi","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2026022021164841700_bib7","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/cea.12792","article-title":"Simultaneously elevated exhaled nitric oxide and serum-eosinophil cationic protein relate to recent asthma events in asthmatics in a cross-sectional population-based study","volume":"46","author":"Mogensen","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"2026022021164841700_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/thoraxjnl-2014-205634","article-title":"External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma","volume":"70","author":"Wagener","year":"2015","journal-title":"Thorax"},{"key":"2026022021164841700_bib9","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"2026022021164841700_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicenter, parallel, double-blind, randomized, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026022021164841700_bib11","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"2026022021164841700_bib12","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"2026022021164841700_bib13","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/thx.50.10.1057","article-title":"Exacerbations of asthma without sputum eosinophilia","volume":"50","author":"Turner","year":"1995","journal-title":"Thorax"},{"key":"2026022021164841700_bib14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0091-6749(95)70128-1","article-title":"Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation","volume":"95","author":"Fahy","year":"1995","journal-title":"J Allergy Clin Immunol"},{"key":"2026022021164841700_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2213-2600(20)30397-0","article-title":"Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicenter, single-blind, parallel group, randomized controlled trial","volume":"9","author":"Heaney","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026022021164841700_bib16","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"2026022021164841700_bib17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","article-title":"Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era","volume":"76","author":"Jackson","year":"2021","journal-title":"Thorax"},{"key":"2026022021164841700_bib18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jaip.2019.11.006","article-title":"T2-\u201clow\u201d asthma: overview and management strategies","volume":"8","author":"Fitzpatrick","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026022021164841700_bib19","doi-asserted-by":"crossref","first-page":"00309","DOI":"10.1183\/23120541.00309-2020","article-title":"Identification and treatment of T2-low asthma in the era of biologics","volume":"7","author":"Kyriakopoulos","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026022021164841700_bib20","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026022021164841700_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13063-017-2384-7","article-title":"A randomized pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomized trial","volume":"19","author":"Hanratty","year":"2018","journal-title":"Trials"},{"key":"2026022021164841700_bib22","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"2026022021164841700_bib23","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022021164841700_bib24","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2147\/COPD.S80091","article-title":"Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function","volume":"10","author":"Bafadhel","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026022021164841700_bib25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaci.2009.11.033","article-title":"Overall asthma control: the relationship between current control and future risk","volume":"125","author":"Bateman","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2026022021164841700_bib26","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.jaip.2020.12.062","article-title":"Factors associated with frequent exacerbations in the UK Severe Asthma Registry","volume":"9","author":"Yang","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026022021164841700_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022021164841700_bib28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1183\/09031936.00012415","article-title":"Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes","volume":"46","author":"Westerhof","year":"2015","journal-title":"Eur Respir J"},{"key":"2026022021164841700_bib29","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/all.12445","article-title":"Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma","volume":"69","author":"Kupczyk","year":"2014","journal-title":"Allergy"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/206\/5\/545\/67000562\/ajrccm_206_5_545.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/206\/5\/545\/67000562\/ajrccm_206_5_545.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:16:56Z","timestamp":1771640216000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/206\/5\/545\/8491716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,9,1]]},"published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202201-0129oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9]]},"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"2022-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}